12/10/24, 4:01 PM 809-P: Oral Semaglutide in Indian Type 2 Diabetes Mellitus patients (SOLID) Study—Twelve Months Follow-up | Diabetes | A…
Split-Screen
Article Navigation
Share Cite Get Permissions
P: CLINICAL THERAPEUTICS—INCRETIN-BASED THERAPIES | JUNE 14 2024
809-P: Oral Semaglutide in Indian Type 2 Diabetes Mellitus
patients (SOLID) Study—Twelve Months Follow-up
SUPRATIK BHATTACHARYYA
Diabetes 2024;73(Supplement_1):809-P
https://doi-org.libproxy1.nus.edu.sg/10.2337/db24-809-P
Background: The oral formulation of semaglutide, a GLP-1R agonist, has emerged as a
promising treatment option for diabesity, demonstrating efficacy in both glycemic parameter
improvement and weight management.
Materials and Methods: Following market launch in India in 2022, we conducted a prospective,
observational cohort study across eight Indian centers to examine the initial utilization patterns of
oral semaglutide in routine clinical practice. The present study enrolled subjects diagnosed with
type 2 diabetes who possessed one year of follow-up data on oral semaglutide use.
Results: A multi-center, open-label, single-arm study evaluated the efficacy and safety of oral
semaglutide monotherapy in 152 patients with type 2 diabetes mellitus. The mean age of the
participants was 50.14 years, and the majority were male (59.86%). The baseline characteristics
included a mean body mass index of 29.82 kg/m2, a mean body weight of 87.17 kg, and a mean
HbA1c of 9.09%. A significant portion of the study population had comorbidities, including
hypertension (46%), dyslipidemia (41%), and hypothyroidism (16%). At baseline, 81.7% of
patients were initiated on the 3 mg dose of oral semaglutide. The primary outcome measures
were the change in HbA1c and body weight from baseline to the follow-up visit after 1 year. The
mean reduction in HbA1c and body weight was 1.81% and 5.03 kg, respectively (P < 0.0001 for
both). The most common adverse events reported were generalized weakness, nausea, dryness
of mouth, and diarrhea. Notably, no hypoglycemia, other serious adverse events, or
discontinuations were observed.
Conclusions: Over a 12-month period, individuals with T2DM demonstrated significant
improvements in key glycemic parameters, including HbA1c, and reduction in body weight,
highlighting the potential of oral semaglutide as a first-line therapeutic option for this population.
Disclosure
S. Bhattacharyya: None.
https://diabetesjournals-org.libproxy1.nus.edu.sg/diabetes/article/73/Supplement_1/809-P/155077/809-P-Oral-Semaglutide-in-Indian-Type-2-Diab… 1/4
12/10/24, 4:01 PM 809-P: Oral Semaglutide in Indian Type 2 Diabetes Mellitus patients (SOLID) Study—Twelve Months Follow-up | Diabetes | A…
© 2024 by the American Diabetes Association
Split-Screen Share Cite Get Permissions
Readers may use this article as long as the work is properly cited, the use is
educational and not for profit, and the work is not altered. More information is
available at
http://www.diabetesjournals.org.libproxy1.nus.edu.sg/content/lic
ense.
View Metrics
Email Alerts
Article Activity Alert
Online Ahead of Print Alert
Latest Issue Alert
Most Read Most Cited
Système International (SI) Units Table
Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International
Expert Panel
713-P: Is There a Correct Time to Measure Fasting Blood Sugar in Persons with Type 2 Diabetes
Melitus?
Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes: Many Differences, Few
Similarities
Elevated First-Trimester Neutrophil Count Is Closely Associated With the Development of Maternal
Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes
https://diabetesjournals-org.libproxy1.nus.edu.sg/diabetes/article/73/Supplement_1/809-P/155077/809-P-Oral-Semaglutide-in-Indian-Type-2-Diab… 2/4
12/10/24, 4:01 PM 809-P: Oral Semaglutide in Indian Type 2 Diabetes Mellitus patients (SOLID) Study—Twelve Months Follow-up | Diabetes | A…
Online ISSN 1939-327X Print ISSN 0012-1797
Split-Screen Share Cite Get Permissions
Journals Books
Diabetes ShopDiabetes.org
Diabetes Care ADA Professional
Clinical Diabetes
Books
Diabetes Spectrum Clinical
Standards of Compendia
Medical Care in
Clinical Compendia
Diabetes
Home
Scientific Sessions
Abstracts News
BMJ Open
Latest News
Diabetes Research
& Care DiabetesPro
SmartBrief
Podcasts About
Diabetes Core About the ADA
Update
Journal Policies
Diabetes Care "On
For Reviewers
Air"
Advertising in ADA
DiabetesBio
Journals
Diabetes Day by
Reprints and
Day
Permission for
Diabetes Core Reuse
Update: Special
Copyright
Editions
Notice/Public
Access Policy
Other
Special Collections
DiabetesPro®
Diabetes Food
Hub™
Insulin Affordability
https://diabetesjournals-org.libproxy1.nus.edu.sg/diabetes/article/73/Supplement_1/809-P/155077/809-P-Oral-Semaglutide-in-Indian-Type-2-Diab… 3/4
12/10/24, 4:01 PM 809-P: Oral Semaglutide in Indian Type 2 Diabetes Mellitus patients (SOLID) Study—Twelve Months Follow-up | Diabetes | A…
Know Diabetes By
Heart™ Split-Screen Share Cite Get Permissions
Resources
ADA Professional Membership
ADA Member Directory
Diabetes.org
Contact Us Cookie Policy Accessibility Terms & Conditions Get Adobe Acrobat Reader
© Copyright American Diabetes Association
https://diabetesjournals-org.libproxy1.nus.edu.sg/diabetes/article/73/Supplement_1/809-P/155077/809-P-Oral-Semaglutide-in-Indian-Type-2-Diab… 4/4
